Study Purpose: This study is for people with Primary Biliary Cholangitis (PBC), a liver disease where the bile ducts in the liver are slowly destroyed. Scientists want to see if a medicine called Saroglitazar Magnesium is safe and works well for these patients.

Important Points:

• The study is open-label, meaning both the patients and doctors know what treatment is being given. This is an extension, so only those who completed a previous study (SARO.21.001) can join.
• Participants must follow strict rules, such as not drinking too much alcohol and not having certain other diseases.
• The study excludes people with severe liver problems, uncontrolled heart issues, or recent surgeries.

Things to Remember:

• If you have any other liver diseases or conditions, you might not be able to join.
• Participants need to agree not to get pregnant during the study.
• If you have allergies to the study medicine, you cannot participate.